LONDON: The death of a nurse has been linked to a weight loss jab due to be assessed by the UK government as a way of easing ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.

Approved for use on the NHS last year and manufactured by pharmaceutical firm Eli Lilly, tirzepatide - also known under brand ...

Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate for if given a role in the incoming Trump ...

NICE has said it expects to evaluate dozens of potential treatments for Alzheimer’s disease over the next few years. Elisabeth Mahase examines what we know about these drugs This year the National ...

Novo Nordisk's (NVO) third-quarter earnings were solid enough to soothe investor jitters and turn the market's attention toward upcoming trial results for a potentially game-changing new weight-loss ...

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

Use of the weight loss drug was also linked to shorter hospital stays. Eli Lilly and Novo Nordisk are the main players in the GLP-1 field, but they're facing competition from compounding pharmacies, ...

NOW 21% 79.12% 78.32% 19.20% 15.30% BlackRock Inc. BLK 21% 81.09% 76.52% 41.79% 40.61% MarketAxess Holdings Inc. MKTX 20% 79.96% 78.86% 54.22% 47.86% Eli Lilly & Co. LLY 20% 81.02% 80.42% 42.85% 40.39 ...

The Silicon Valley chip designer's stock has climbed 12% in November, with its value tripling so far in 2024. Following this ...